CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue		$ 14,256	$ 13,749	$ 28,759	$ 24,166
Expenses:
Research and development	[1]	9,954	9,425	18,922	23,997
Selling, general and administrative	[1]	17,056	19,278	33,798	38,461
Impairment of long-lived assets (non-cash)		2,951		2,951
Restructuring and related expenses	[1]		1,169		2,743
Total expenses		29,961	29,872	55,671	65,201
Loss from operations		(15,705)	(16,123)	(26,912)	(41,035)
Interest expense (non-cash)		(644)	(568)	(1,273)	(1,118)
Interest income and other income (expense), net		1,128	2,504	2,562	5,483
Loss before income taxes		(15,221)	(14,187)	(25,623)	(36,670)
Provision for income tax expense		(1,308)	(1,458)	(2,570)	(1,063)
Net loss		(16,529)	(15,645)	(28,193)	(37,733)
Other comprehensive loss:
Net unrealized gain (loss) on available-for-sale investments		19	(337)	43	(271)
Total comprehensive loss		$ (16,510)	$ (15,982)	$ (28,150)	$ (38,004)
Net loss per share:
Net loss - basic (in dollars per share)		$ (0.34)	$ (0.28)	$ (0.58)	$ (0.63)
Net loss - diluted (in dollars per share)		$ (0.34)	$ (0.28)	$ (0.58)	$ (0.63)
Shares used to compute net loss per share - basic		48,747	56,682	48,515	59,791
Shares used to compute net loss per share - diluted		48,747	56,682	48,515	59,791
Viatris collaboration agreement
Revenue:
Total revenue		$ 14,256	$ 13,743	$ 28,759	$ 24,154
Collaboration revenue
Revenue:
Total revenue			$ 6		$ 12

[1] Amounts include share-based compensation expense as follows: